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Circulating Dendritic Cells Isolated from Healthy Seropositive Donors
Are Sites of Human Cytomegalovirus Reactivation In Vivo
Matthew B. Reeves, John H. Sinclair
University of Cambridge, Department of Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom
Primary infection with human cytomegalovirus (HCMV) is generally asymptomatic in healthy individuals and results in a life-
long infection of the host. In contrast, in immunosuppressed transplant recipients and late-stage AIDS patients, HCMV infec-
tion and reactivation can result in severe disease or death. In vivo, latency is established in bone marrow CD34 progenitor cells
with reactivation linked with their differentiation to macrophages and dendritic cells (DCs). However, previous analyses have
relied on ex vivo differentiation of myeloid progenitor cells to DCs in culture. Here, we now report on the isolation and analysis
of circulating blood myeloid DCs, resulting from natural differentiation in vivo, from healthy HCMV-seropositive carriers. We
show that these in vivo-differentiated circulating DCs are fully permissive for HCMV and exhibit a phenotype similar to that of
monocyte-derived DCs routinely used for in vitro studies of HCMV. Importantly, we also show that these DCs from healthy
HCMV-seropositive donors carry HCMV genomes and, significantly, are typically positive for viral immediate-early (IE) gene
expression, in contrast to circulating monocytes, which carry genomes with an absence of IE expression. Finally, we show that
HCMV reactivation from these circulating DCs is enhanced by inflammatory stimuli. Overall, these data argue that the differen-
tiation in vivo of myeloid progenitors to circulating DCs promotes the reactivation of HCMV lytic gene expression in healthy
individuals, thereby providing valuable confirmation of studies performed using in vitro generation of DCs frommyeloid pre-
cursors to study HCMV reactivation.
Primary infection of healthy individuals with human cytomeg-alovirus (HCMV) normally results in an asymptomatic infec-
tion of the host. However, primary infection of neonates or infec-
tion with or reactivation of latent virus in immunosuppressed
transplant patients and immunocompromised late-stage HIV pa-
tients, who have developed AIDS, can result in significant mor-
bidity and mortality (1–3). Consequently, serious health risks
posed by reactivation of latentHCMVhave resulted in a concerted
effort by a number of laboratories to further define the cell types
and mechanisms involved in HCMV latency and reactivation.
The current consensus is that HCMV can establish a latent
infection of pluripotent CD34 mononuclear cells (4–8). How-
ever, carriage of the virus appears to be restricted only to certain
cell types within the hematopoietic system, in particular, cells of
the myeloid lineage such as monocytes, their circulating progeni-
tors, and subsequent derivatives (9–14). This carriage of viral ge-
nomes occurs in the absence of any significant viral lytic gene
expression (reviewed in reference 15); hence, cells of the myeloid
lineage represent an important site of latency and persistence in
the host. This is nomore exemplified than by clinical observations
that leukocyte depletion of peripheral blood prior to transfusion
significantly diminished the incidence of HCMV transmission to
recipients (16–18).
Pertinent to this report, a number of studies of both experi-
mental and natural latency have illustrated that the in vitro differ-
entiation of myeloid progenitor cells to terminally differentiated
myeloid dendritic cell (DC) phenotypes results in the induction of
HCMV reactivation from these latently infectedmyeloid cell types
(5, 12, 19–23). Thesemodels have relied on in vitro differentiation
to cell types that are defined as dermal (interstitial) or epidermal
(Langerhans)-like cell types based on the expression of a panel of
cell surface markers identified on corresponding cells directly iso-
lated ex vivo (20, 24–29). Therefore, these data would predict that
circulating DCs were sites of HCMV carriage in vivo and, further-
more, that these cells might be sites of reactivation in vivo. How-
ever, crucially, while a wealth of in vitro data supports this prevail-
ing hypothesis, it has never been definitively shown that naturally
occurring DCs derived from healthy seropositive individuals are
sites of genome carriage and, importantly, sites of HCMV reacti-
vation. Indeed, a previous study of CD11c dendritic cells isolated
from buffy coats of healthy volunteers has suggested that the well-
documented immunoparalysis observed following infection of in
vitro-differentiated DCs (20, 30–37) is not observed when circu-
lating DCs are similarly infected in vitro with HCMV (38). Al-
though these data concern lytic infection, they exemplify the need
for a direct analysis of HCMV latency and reactivation in DCs.
In this study, we have sought to formally address whether
DCs directly isolated ex vivo from healthy seropositive donors
are indeed sites of HCMV latency and reactivation. Here, we
show that the purification of circulating blood DCs, which ex-
press a cell surface phenotype comparable to that of monocyte-
derived DCs (MoDCs) ex vivo, results in the detection of
HCMV genome-positive cells in healthy aviremic seropositive
donors. Furthermore, the carriage of viral genomes is concom-
itant with the detection of HCMV lytic gene transcription in
these cells and, ultimately, the recovery of infectious virus from
them. Importantly, we show that monocytes isolated concom-
itantly from the same donors are immediate-early (IE) tran-
script negative, consistent with in vivo differentiation to a my-
eloid DC as a trigger for HCMV reactivation. Interestingly, we
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also observed that a number of inflammatory stimuli could
significantly enhance the level of reactivation observed in these
purified circulating DC populations, consistent with the con-
cept that inflammation may play an important role in efficient
reactivation, particularly in clinical scenarios (1, 23, 39).
MATERIALS AND METHODS
Ethics statement. All research describing studies on primary human ma-
terial with HCMV were assessed and approved by the Cambridge Local
Research Ethics Committee. Informed consent was given for the collec-
tion of venous blood samples from healthy donors, and the collection was
performed in accordance with established guidelines for the handling and
processing of said tissue by the Cambridge Local Research Ethics Com-
mittee.
Cells and tissue culture. Human foreskin fibroblasts (HFFs) were
maintained in Eagle’sminimal essentialmedium containing 10% fetal calf
serum (EMEM-10) (Sigma-Aldrich, Poole, United Kingdom) and incu-
bated at 37°C and in 5% CO2 by following standard procedure for tissue
culture. Briefly, total peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll density-dependent centrifugation and then incubated
with an antibody cocktail containing anti-CD3, -CD7, -CD16, -CD56,
and -CD123 microbeads and separated on a magnetically activated cell
sorting (MACS) column. The resultant flowthrough was confirmed to be
T-cell receptor / (CR/) negative and then incubated with an anti-
CD4microbead-conjugated antibody. The enriched fraction bound to the
column was rescued and represented the DC fraction. Typically, the yield
of DCs was around 0.5 to 1% of the total PBMC count. Where appropri-
ate, DCs were stimulated with lipopolysaccharide (LPS; 500 ng/ml; Sig-
ma-Aldrich, Poole, United Kingdom) or interleukin 6 (IL-6; 50 ng/ml;
Peprotech EC, United Kingdom) to promote maturation or activation,
respectively.
Virus infection and indirect immunofluorescence. Following isola-
tion, blood DCs were cultured on 8-well chamber slides in X-vivo 15
medium for 3 h and then infected overnight with HCMV strain TB40/e.
To detect IE gene expression, infected cells were washed in phosphate-
buffered saline (PBS) and fixed for 10 min in 4% paraformaldehyde at
room temperature. After being permeabilized with 0.1% Triton X-100 in
PBS, cells were incubated with monoclonal mouse anti-IE antibody (1:
1,000 dilution in PBS; Millipore) for 1 h at room temperature. After a
washing with PBS, the bound antibodies were detected using Alexa Fluor
594 (Millipore, Billerica,MA)-conjugated goat anti-mouse immunoglob-
ulins (1:1,000 dilution in PBS) together with nuclear stain Hoechst (1:
1,000 dilution in PBS) in the dark for 1 h at room temperature. To detect
pp28 expression, cells 5 days postinfection were fixed and stained with
rabbit anti-pp28 antibody (1:500 in PBS; Abcam, Cambridge, United
Kingdom) and then detected using Alexa Fluor 594-conjugated goat anti-
mouse immunoglobulins (1:1,000 dilution in PBS; Millipore) together
with nuclear stain Hoechst (1:1,000 dilution in PBS; Sigma, Poole, United
Kingdom) in the dark for 1 h at room temperature. After a washing with
PBS, infected cells were visualized using a Nikon immunofluorescence
microscope.
Nucleic acid isolation and analysis. DNA isolation was performed
using a sodium perchlorate method described previously which has been
optimized for the isolation and detection of viral genomes from naturally
latentmononuclear cells (40). Briefly, 106 cells were resuspended in 600l
of buffer A (100 mMNaCl, 5 mM; pH 8.0), lysed with 10% SDS (125 l),
and then incubated with 5 M sodium perchlorate (150 l). DNA was
isolated by phenol-chloroform extraction and isopropanol precipitation.
To eliminate salt contamination, total DNA was then dialyzed overnight
at 4°C in circulating Tris-EDTA buffer. To analyze gene expression, total
RNA was extracted from 106 cells using the RNeasy kit as described by
the manufacturer (Qiagen, Sussex, United Kingdom) Contaminating
genomic DNA was removed by a DNase I digestion (Promega, Madison,
WI), followed by production of first-strand cDNA using the Promega RT
system. Standard PCR was carried out using 2 PCR MasterMix (Pro-
mega) containing DNA polymerase, MgCl2, and deoxynucleoside
triphosphates (dNTPs). To detect endogenous viral nucleic acids, two
approaches were used; they have been described previously. Briefly, a
single round (65 cycles) of IE-specific PCR (94°C for 40 s, 55°C for 40 s,
and 72°C for 90 s) was used to amplify DNA (310 bp) or cDNA (196 bp)
products using sense primer 5=-CGT CCT TGA CAC GAT GGA GT-3=
and antisense primer 5=-ATT CTT CGG CCA ACT CTG GA-3=. Follow-
ing gel electrophoresis and Southern blotting, IE-specific sequences were
detected using a 32P-radiolabeled probe generate using sense primer 5=-
CCCTGATAATCCTGACGAGG-3= and antisense primer 5=-CATAGT
CTGCAGGAACGTCGT-3=. Alternatively, nested IE primers were used
to amplify target sequences by PCRwith the following cycling conditions:
95°C for 5 min, then 20 to 35 cycles of 94°C for 1 min, 55°C for 40 s, and
72°C for 40 s, and then a final extension at 72°C for 10 min. IE72 was
amplifiedwith sense primer 5=-CATCCACATCTCCCGCTTAT-3= and
antisense primer 5=-CAC GAC GTT CCT GCA GAC TAT G-3= followed
by nested PCR with sense primer 5=-GCG CCA GTG AAT TTC TCT TC
and antisense primer 5=-ACGAGAACCCCGAGAAAGATG, yielding a
final nested product of 302 bp (DNA) or 131 bp (cDNA). A 548-bp actin
product was amplified using sense primer 5=-GCT CCG GCA TGT
GCA-3= and antisense primer 5=-AGG ATC TTC ATG AGG TAG T-3=
under the same PCR conditions.
ChIP and analysis. All procedures were performed essentially as de-
scribed previously (40). Briefly,DCswere fixedwith 1% formaldehyde (10
min) and then lysed and sonicated to fragment DNA. DNA associated
with histoneswas immunoprecipitatedwith control serum (Sigma, Poole,
United Kingdom), anti-acetyl histone H4 antiserum (chromatin immu-
noprecipitation [ChIP] grade, 1:200 dilution; Upstate Biotechnology,
Charlottesville, VA), anti-dimethyl lysine 4 histone H3 antiserum (ChIP
grade, 1:200 dilution; Upstate Biotechnology), or anti-heterochromatin
protein 1 (anti-HP1) antiserum (1:200 dilution; Serotec, Oxford, United
Kingdom). For detection of the major immediate early promoter (MIEP)
of HCMV, DNA from disrupted nucleosomes was precipitated and am-
plified by PCR with sense primer 5=-TGG GAC TTT CCT ACT TGG-3=
and antisense primer 5=-CCAGGCGATCTGACGGTT-3=, complemen-
tary to positions272 and13 relative to the MIEP start site. Amplified
productswere detected using a PCRproduct generated using sense primer
5=-ATT ACC ATG GTG ATG CGG TT-3= and antisense primer 5=-GGC
GGA GTT GTT ACG ACA T-3=, which was labeled with [32P]dCTP to
allow detection by Southern blotting. All amplifications by PCR were
performed with 2 Mastermix (Promega, Madison, WI). The cycle pa-
rameters for amplification by PCR were 95°C for 5 min and then 20 to 50
cycles at 94°C for 40 s, 50°C for 40 s, and 72°C for 90 s.
Amplification of the HS4 locus of the gamma globin gene by PCR was
performed using sense primer 5=-TGGCATCTAGCGCAATGACTT-3=
and antisense primer 5=-GGG CAA GCC ATC TCA TAG CTG-3=, which
have been used in previous analyses of this region.
Cell surface phenotype flow cytometry analysis. A total of 105 cells
were pelleted at 400  g for 5 min and were then resuspended in the
residual volume. The cells were incubated with 3l of fluorescein isothio-
cyanate (FITC)-conjugatedmouse anti-human CD1c, 5l of Alexa Fluor
488-conjugated mouse anti-human E-cadherin (R&D Systems, Abing-
don, United Kingdom), 3 l of phycoerythrin (PE)-conjugated mouse
anti-human major histocompatibility complex class I, or 3 l of allophy-
cocyanin (APC)-conjugated mouse anti-human CD83, HLA-DR, or
CD86 or the appropriate fluorochrome-conjugated mouse isotype con-
trol for 20 min in the dark. Following a washing in 10 volumes of PBS,
the cells were pelleted at 400 g for 5min andwere resuspended in 500l
of PBS before analysis by flow cytometry (BD FACScalibur or BD FAC-
Ssort). Data handling was performed using WinMDI2.9 software. All an-
tibodies were fromBDLife Sciences (Franklin Lakes, NJ) unless otherwise
stated. No differences in cell surface phenotype were observed whether
DCs from seropositive or seronegative donors were analyzed.
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RESULTS
Dendritic cells directly isolated from peripheral blood are per-
missive for HCMV infection. To isolate circulating DCs, we used
a two-stage procedure that involved depletion of T lymphocytes,
NK cells, andmonocytes followed by a positive selection forCD4
cells. A routine analysis of the isolated cells (which represented
about 0.5% of the total PBMC) identified them as HLA-DR pos-
itive and TCR/, CD14, and CD19 negative (Fig. 1A), suggestive
of enrichment of myeloid DCs (routinely 95%). Further char-
acterization showed that these blood DCs were HLA-ABC, HLA-
DR, and CD1c positive, CD83dim and CD86dim, and E-cadherin
negative (Fig. 1B). This phenotype was consistent with a more
immature dermal, and not Langerhans, DC phenotype (25), sim-
ilar to that observed for classicalMoDCs (20, 25), which have been
used routinely to study HCMV latency and reactivation. Taken
together, these data suggested that the circulating blood DCs iso-
lated were predominantly of a dermal/interstitial-like phenotype,
consistent with previous reports for the isolation ofmyeloid blood
DCs from healthy donors (40, 41).
Given the phenotypic similarity between circulating blood
DCs andMoDCs, we next askedwhether these immature bloodDCs
were permissive for HCMV infection. Directly isolated blood DCs
were infected with HCMV and stained for IE and pp28 gene expres-
sion at 1 and 5 days postinfection, respectively (Fig. 2). Indirect im-
munofluorescence for IE72/86 expression, 24 h postinfection (hpi),
showed that directly isolated DCs supported HCMV lytic gene ex-
pression (Fig. 2A), consistent with a previous analysis of circulating
DCs (38). Furthermore, we observed that the infection was not lim-
ited to IE protein expression, since the expression of the structural
tegument protein, pp28, was clearly evident by 5 days postinfection
(Fig. 2B). Finally, the level of infectionof thepurifiedDCswas similar
to that observed following the infection of MoDCs generated from
the same donor cells (Fig. 2C).
Directly isolated DCs are HCMV genome positive and sup-
port the reactivation of HCMV ex vivo. Having established that
we could isolate purified populations of circulating DCs that sup-
ported lytic gene expression, we next asked whether these cells
were sites of HCMV genome carriage in vivo. In order to test this,
DCs were isolated directly from the blood concomitantly from
seropositive and seronegative donors and analyzed using an IE-
specific nested PCR in a number of independent analyses. The
FIG 1 Circulating myeloid dendritic cells can be isolated from peripheral
blood. (A) Flow cytometric analysis was performed on peripheral blood
mononuclear cells stained with FITC-conjugated anti-TCR/, -CD14, and
-CD19 antibodies (top right) or isotype-matched antibody controls (top left).
Following magnetic column depletion with anti-CD3, -CD7, -CD16, -CD56,
and -CD123 antibodies, the unbound fraction was stained with FITC-conju-
gated anti-TCR/, -CD14, and -CD19 antibodies (bottom). CD4-positive
cells were depleted from the unbound fraction and stained with FITC-conju-
gated anti-TCR/, -CD14, and -CD19 antibodies and a PE-conjugated anti-
HLA-DR antibody. (B) Isolated DCs were stained with a panel of cell surface
markers (filled histogram) or an isotype-matched control (open histogram)
immediately postisolation.
FIG 2 Directly isolated DCs are permissive for HCMV gene expression. (A)
Three hours postisolation, DCs were infected with a myelotropic stock of
TB40/e and stained for IE gene (a) and nuclear DNA (b) 24 h postinfection.
Themerged image (c) shows nuclear IE gene expression. DCmorphology after
isolation and infection is shown in an IE gene-positive cell shownmerged with
bright-field image (d). (B) TB40/e-infected (a) ormock-infected (b) DCs were
costained for pp28 expression and nuclear DNA 5 days postinfection. (C) DCs
and monocyte-derived DCs infected with TB40/e were stained for IE (bars 1
and 2) or pp28 (bars 3 and 4) expression, and the number of antigen-positive
cells was determined. Data show enumeration from 10 fields of view per-
formed in triplicate. dpi, days postinfection.
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collated data clearly show that viral genomes were detectable in
theDCs of 6 seropositive, but not seronegative, donors tested (Fig.
3A and B). It is interesting that although all seropositive donors
were uniformly viral genome positive, the ability to detect viral
genomes in the DCs of some donors compared to others differed.
This was particularly evident with donor 04 (Fig. 3A, lane 4). It is
interesting that this donor had recently seroconverted (within 1
year) around the time of our analyses, and the relative difficulty of
detection of viral genomes in the donor’s DCs was mirrored
upon analyses of that individual’s mobilized CD34 cells or
CD14 monocyte populations also (12), suggesting that the
latent load may accumulate with time. We then performed a
second analysis using a single-round PCR followed by a radio-
labeled probe detection step to provide further confirmation
that we could detect HCMV genome sequences by PCR in cir-
culating DCs directly isolated from selected healthy seroposi-
tive donors (Fig. 3C and D).
Confident that we could detect the carriage of HCMV genome
in purified populations of circulating DCs isolated from healthy
seropositive persons, we next addressed whether we could detect
viral transcription. The carriage of viral genomes in the circulating
monocytes of healthy seropositive donors has been shown to oc-
cur in an absence of detectable viral lytic gene expression (42).
However, it is well established that differentiation ofmonocytes to
MoDCs in ex vivo culture results in reactivation of latent virus,
which would suggest that circulating DCs could be potential sites
of reactivation in vivo. Thus, we next analyzed the transcriptional
state of the HCMV genomes in the circulating DCs (Fig. 4). To do
this, we performed a reverse transcription-PCR (RT-PCR) analy-
sis of circulating DCs immediately after isolation from peripheral
blood. The data show that IE gene expression is detectable in DCs
isolated directly from seropositive donors (3/4 donors) (Fig. 4).
Again, the donor in whom we failed to detect IE gene expression
was donor 04, the donor of the DCs in which it was more difficult
to detect viral genomes (Fig. 3). Furthermore, the in vitro differ-
entiation of donor 04’s monocytes to MoDCs also resulted in a
failure to detect the expression of IE gene expression, unlike with
donor 01 (Fig. 4B). Additionally, the failure to detect IE gene tran-
scription in concomitantly isolated monocytes from the remain-
ing donors (Fig, 4B and D) is indicative that these healthy volun-
teers were not viremic at the time of blood donation. In total, we
were able to detect the expression of IERNA in the circulatingDCs
of 6/7 donors tested for reactivation (Fig. 4; see also Fig. 6).
Consistent with the detection of viral lytic gene expression in
the isolated DCs, chromatin immunoprecipitation analyses of the
histone occupancy of theMIEP in the circulating DCs of a healthy
seropositive donor was also consistent with IE transcription (Fig.
5). Specifically, the MIEP was predominantly immunoprecipi-
tated with antibodies recognizing dimethylated H3-K4 and acety-
lated H4 histones (bothmarkers of transcriptional activation) but
not themarker of transcriptionally repressed chromatinHP1 (Fig.
5A). Again, an analysis of the same donormonocytes exhibited the
opposite phenotype. The MIEP in these cells was associated pre-
dominantly with the marker of transcriptional repression, HP1
(Fig. 5B). Furthermore, the in vitro differentiation to a DC phe-
notype was concomitant with the MIEP being predominantly as-
sociated with acetylated histones, consistent with these cells sup-
porting HCMV reactivation (12, 21) and our previous studies of
CD34 cells and the DCs derived from these (12).
ReactivationofHCMVfromDCs is elevatedupon inflamma-
tory stimulation and results in the formation of infectious cen-
ters. These data suggested that during the natural differentiation
of bloodDCs in vivo, a switch from anHCMV latent to anHCMV
reactivating phenotype could be occurring. However, in vivo,
symptomatic HCMV reactivation and disease are often associated
with immunosuppression and highly inflammatory environ-
ments, and thus, we next asked whether known inflammatory
mediators impacted the level of HCMV reactivation from circu-
lating DCs ex vivo. Circulating DCs, isolated from healthy donors,
were stimulated with a number of inflammatory mediators and
FIG 3 Detection of HCMVDNA sequences in circulating blood DCs of seropositive donors. (A and B) Nested PCR analysis of DCs frommultiple seropositive
(donors 01 to 04, 07, 08, 011, and 012), seronegative (donors 05, 06, 09, and 010), or water (panel A, lanes 9 and 10) and DNA (panel B, lane 5) controls was
performed using IE gene-specific (a) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DNA-specific (b) PCRs. Nested PCR gave rise to a 312-bp
product fromHCMVDNA. (C andD) A single-round IE gene PCR analysis on three seropositive (donors 01, 02, and 08), three seronegative donors (05, 06, and
010), and a water (panel C, lane 5) or DNA (panel C, lane 6, and panel D, lane 3) control was analyzed by Southern blotting and probing with an IE gene-specific
probe that detected a 310-bp product. A GAPDH PCR was used to confirm the isolation of DNA.
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analyzed for IE RNA (24 h poststimulation) or IE gene-positive
fibroblasts (21 days after coculture with 5  105 mononuclear
cells) (Fig. 6). The latter approach, the direct staining of cocultures
rather than 50% tissue culture infective dose (TCID50) analysis on
supernatants for infectious virus, was employed because we could
obtain only limited numbers of circulating DCs and only a small
minority of these would likely be HCMV genome positive (13)
and is an approach that has been used previously for studying
reactivation events fromnatural latency with limited cell numbers
(12, 20, 43). As observed before (Fig. 4A), circulating DCs showed
detectable IE gene expression (Fig. 6A), and this was elevated fol-
lowingmaturation with LPS or stimulation with IL-6 (Fig. 6A and
B) or tumor necrosis factor alpha (TNF-) (Fig. 6B), two cyto-
kines that correlate with HCMV reactivation episodes in vivo (11,
44). We next analyzed infectious-virus production in the DC co-
cultures, and as an additional set of controls, we analyzed infec-
tious virus production fromMoDCs and the monocyte- and DC-
depleted fraction (predominantly lymphocytes) from naturally
latent donors. Consistent with previous analyses (12, 21), HCMV
reactivation was detectable in immature MoDCs after ex vivo dif-
ferentiation of monocytes to MoDCs in culture, and this was ele-
vated following activation with LPS and IL-6 (Fig. 6C). Similarly,
directly isolated DCs exhibited a similar response: virus reactiva-
tion was elevated by further stimulation with LPS or IL-6
(Fig. 6C). In contrast, noHCMVreactivationwas detectable in the
monocyte- and DC-depleted fraction (predominantly lympho-
cytes), consistent with these cells not being major sites of viral
persistence in the peripheral blood (14). Taken together, these
data argue that naturally circulating DCs can support the reacti-
vation of HCMV ex vivo and that further inflammatory stimula-
tion augments the reactivation of virus observed in DCs.
DISCUSSION
There exists a wealth of data from a number of laboratories that
strongly supports the myeloid lineage as a major site of HCMV
latency and reactivation in vivo (reviewed in references 19 and 45).
These data are consistent with the view that HCMV latency is
established in early progenitor cells in the bone marrow, the viral
genome then persists in the myeloid/monocyte compartment in
the peripheral blood without detectable viremia, and finally, ter-
minal differentiation of latent monocytes to a macrophage or DC
phenotype instigates a chain of events leading to reactivation of
the virus in the periphery due to a more favorable transcriptional
environment for MIEP activity and that this is likely augmented
by inflammatory signaling in vivo (1, 46). The paucity of circulat-
ing myeloid DCs in the peripheral blood compartment has led
many investigators to use in vitro differentiation of early myeloid
progenitors to model HCMV reactivation (4, 5, 20–22, 47–49).
FIG 4 Detection of IE RNA transcripts in circulating bloodDCs of seropositive donors. (A) RNA prepared fromDCs directly isolated from the peripheral blood
of seropositive (donors 04 and 01) and seronegative (donors 05 and 06) donors was amplified in an IE gene RT-PCR. Water or HCMVDNA was amplified as a
control for the viral PCRs (lane 5 and 6). Amplified products were then analyzed by Southern blotting with an IE gene-specific probe. (B) Monocytes isolated
from donors 04, 01, and 05 were analyzed either directly postisolation (lanes 1, 3, and 5) or after differentiation to MoDCs (lanes 2, 4, and 6) for IE RNA or
GAPDH expression by Southern blotting. A log dilution of viral DNA was used as a positive control (lanes 7 to 10). (C and D) RNA extracted from DCs (C) or
monocytes (D) isolated from healthy seropositive (donors 02 and 03) or seronegative (donors 05 and 06) donors was analyzed using a nested intron-spanning
RT-PCR for IE72 gene expression. Viral DNA was amplified as a control (lane 5). GAPDH controls are shown (lanes 1 to 5).
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However, we wished to determine whether the robust link be-
tween HCMV reactivation and experimental differentiation of
monocytes to DCs ex vivo was recapitulated in differentiated cir-
culating myeloid DCs in vivo: in that case, direct isolation of the
DC compartment directly from peripheral blood of healthy sero-
positive donors should yield genome-positive cells that can sup-
port HCMV reactivation without further ex vivo differentiation.
Herein, we have shown that CD1c-positive myeloid DCs from
peripheral blood are phenotypically similar to MoDCs based on
cell surface marker expression (20, 40). Consistent with their cel-
lular phenotype, the circulating DCs exhibited the same permis-
siveness for HCMV as MoDCs (50): infection of the cells directly
postisolation resulted in the detection of IE protein-positive cells
and, by day 5, pp28-positive cells. Thus, circulating DCs encoun-
tering HCMV in vivo are likely to be fully permissive for HCMV
infection.
More pertinent to our ongoing studies of HCMV latency and
reactivation, the detection of transcriptionally active genomes in
the circulating DCs of healthy seropositive donors is highly sup-
portive of the hypothesis that predicts (based ondata derived from
studies using in vitrodifferentiation) that terminally differentiated
myeloid cells such as DCs supportHCMV reactivation in vivo.We
note that these analyses represent a global analysis of purified DC
populations, and thus, there is the potential that during the puri-
fication we may isolate a minor contaminating fraction. Arguing
against this is that the isolation of CD34 hematopoietic cells and
their derivatives, CD14monocytes, lymphocyte populations, or
granulocytes using similar procedures does not result in the de-
tection of IE RNA-positive cells (5–7, 12, 14, 21, 42, 51, 52). Iso-
lation of a contaminating cell only in our DC isolations and not
any of these other procedures appears highly unlikely but cannot
be dismissed. These caveats aside, we were particularly intrigued
by the identification of IE gene expression in purified DCs in the
absence of any additional stimulation, which suggests that the
normal differentiation of DCs in vivo is sufficient to trigger
HCMV reactivation. While we cannot formally rule out the pos-
sibility that the protocol for isolating circulating DCs resulted in
the activation of the cells and, pertinently, activation of theMIEP,
we note that the isolation of circulating DCs was complete in less
than 3 h and that activation of theMIEP does not occur in mono-
FIG 5 TheMIEP in circulating DCs is predominantly associated withmarkers
of transcriptional activation. (A) Chromatin immunoprecipitation assays
were performed on seropositive DCs with rabbit IgG (lane 2), anti-dimethy-
lated histoneH3-K4 (lane 3), anti-acetylatedH4 (lane 4), anti-rat IgG (lane 5),
or anti-HP1 (lane 6) antibodies. DNA amplified in an MIEP-specific PCR
was then analyzed by Southern blotting using an MIEP-specific probe. Alter-
natively, samples were amplified using primers against the HS4 region of the
gamma globulin gene. (B) Monocytes isolated from the same donor were
either subjected to ChIP (lanes 1 to 3) or differentiated to MoDCs and then
subjected toChIP analysis (lanes 4 to 6). Immunoprecipitationwith IgG (lanes
1 and 3), anti-HP-1 (lanes 2 and 5) or anti-acetylated histone H4 (lanes 3 and
6) was performed, and samples were amplified in an MIEP PCR and analyzed
by Southern blotting.
FIG 6 Inflammatory stimulation of DCs enhances reactivation ofHCMV. (A)
Isolated DCs from a seropositive (donor 013) or seronegative (donor 014)
donor were cultured alone (lane 1) or with LPS (lane 2) or IL-6 (lane 3) and
analyzed for IE72 and GAPDH RNA expression 16 h poststimulation. (B)
Isolated DCs from two further seropositive donors (donors 015 and 016) were
left unstimulated (lanes 1 and 5) or stimulated with IL-6 (lanes 2 and 6), LPS
(lanes 3 and 7), or TNF- (lanes 4 and 8) and analyzed for IE72 or GAPDH
RNA expression 16 h poststimulation. (C) To test for viral reactivation, 5 
105 MoDCs (lanes 1 to 3), directly isolated DCs (lanes 4 to 6), or DC- and
monocyte-depleted cells (lanes 7 to 9) were cultured alone (M) or with LPS (L)
or IL-6 (I6) and then cocultured with fibroblasts for 21 days. The fibroblast
monolayer was then stained for IE gene expression and the average number of
IE gene-positive foci scored from 5 fields of view.
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cytes isolated in a similar way (data shown herein and references
12 and 14). This suggests that circulating DCs are capable of sup-
porting reactivation of viral lytic gene expression in vivo. Further-
more, we fully appreciate that it is impossible to formally preclude
the possibility that the isolated circulating DCs were undergoing a
de novo infection of HCMV in vivo at the time of harvest. How-
ever, we have performed our analyses on healthy aviremic donors,
and thus, we assume that there is minimal de novo infection of
circulating DCs occurring at the times of analyses. Furthermore,
concomitant analyses of donors’ monocytes showed that these
cells were not IE transcript positive, suggesting that these donors
were not viremic at the time of analysis. Notwithstanding this, if
circulating DCs do express IE RNA, then our data support the
view that DCs could be an important site of viral reactivation in
vivo. Indeed, it is very likely that this reactivation of viral IE gene
expression in circulating DCs in vivo is driven by the differentia-
tion of DC precursors to a DC phenotype and would argue that
sporadic reactivation events, albeit at very low frequency, rou-
tinely occur upon DC differentiation in vivo as HCMV genome-
positive myeloid progenitors differentiate into DCs. Whether this
reactivation in vivo is abortive or fully permissive is still uncertain,
but our data would suggest that circulating DCs are potential sites
of reactivation of the initial events necessary for infectious-virus
production. It is possible, however, that the reactivation of IE gene
expression in the circulating DCs of healthy individuals is suffi-
cient to trigger their recognition by the high numbers of IE-spe-
cific cytotoxic T cells (CTLs) known to be present in healthy sero-
positive donors, which results in their rapid elimination by a
normal IE-specific CTL response. Thismodel would be consistent
with the well-established high frequency of memory CTLs di-
rected against HCMV—the possible result of a constant reprim-
ing of the immune system (53). Indeed, in the absence of this
normal CTL response, such reactivation events would become
uncontrolled, resulting in the severe disease observed in immuno-
compromised patients (1, 2).
In conclusion, to date it has been hypothesized that differenti-
ation of myeloid progenitor cells to differentiated macrophages
and DCs in vivo results in the reactivation of latent virus (5, 8, 12,
23, 42, 54). However, this hypothesis has been based on the ex vivo
differentiation of myeloid progenitors. We now show that differ-
entiated myeloid DCs of healthy seropositive HCMV carriers in
vivo are also sites ofHCMVreactivation. These data provide direct
evidence for the hypothesis thatmyeloid cell differentiation in vivo
is an important event for the initiation of HCMV reactivation.
Furthermore, they provide strong support for the use of experi-
mental latency models employed by a number of laboratories
looking to understand the mechanisms essential for the mainte-
nance of HCMV latency and subsequent control of reactivation in
the cells of the myeloid lineage.
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